NCT03610958 is a NA clinical trial of Epitomee Device in Overweight, sponsored by Epitomee medical.

Who is sponsoring NCT03610958?

NCT03610958 is sponsored by Epitomee medical.

What drugs are being tested in NCT03610958?

Interventions in NCT03610958: Epitomee Device.

What condition does NCT03610958 study?

NCT03610958 studies Overweight, Obesity.

Is NCT03610958 still recruiting?

NCT03610958 is currently completed. Last updated 18 August 2021.

Last reviewed 2021-08-18 · How we verify

NCT03610958

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Performance Evaluation of the Epitomee Device for Enhancing Satiety and Weight Loss.

Completed NA Last updated 18 August 2021

What this trial tests

NA trial testing Epitomee Device in Overweight in 78 participants. Completed in 4 September 2018.

Timeline

4 September 2014

Primary endpoint
4 September 2018

4 September 2018

Quick facts

Lead sponsor	Epitomee medical
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	78
Start date	4 September 2014
Primary completion	4 September 2018
Estimated completion	4 September 2018
Sites	1 location across Israel

Drugs / interventions tested

Epitomee Device

Conditions studied

Overweight — all drugs for Overweight →
Obesity — all drugs for Obesity →

Sponsor

Epitomee medical

Who can join

Adults 21 to 65, any sex, with Overweight or Obesity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Study design to demonstrate the safety and performance of the Epitomee Device

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Recent advances in therapies utilizing superabsorbent hydrogel technology for weight management: A review.
Aronne LJ, Anderson JE, Sannino A, Chiquette E. · · 2022 · cited 12× · PMID 35664250 · DOI 10.1002/osp4.574
Effects of an oral biodegradable device used for 12 weeks on weight reduction, cardiovascular risk factors, satiety, snacking, and meal size.
Shirin H, Neeland IJ, Ryan DH, de Luis D, et al · · 2023 · cited 9× · PMID 38125654 · DOI 10.1016/j.obpill.2023.100094

Verify or expand the search:

Other trials of Epitomee Device

Trials testing the same drug.

NCT04485936 — Evaluation of the Effect of Epitomee Device on Gastric Emptying Rate in Healthy Subjects · NA · completed

Other recruiting trials for Overweight

Currently open trials in the same condition.

NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
NCT07472881 — Multi-Acupoint Laser Therapy for Body Shape and Composition in Obese Menopausal Women · NA · recruiting
NCT07465965 — A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults · Phase 1 · recruiting
NCT07407348 — A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the · Phase 1 · recruiting
NCT07400653 — A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) · Phase 3 · recruiting

Other Epitomee medical trials

Trials by the same sponsor.

NCT04994769 — The Effect of Extended Use of the EPITOMEE CAPSULE (ELECT) · NA · completed
NCT04222322 — The Effect of Epitomee Capsule on Body Weight in Patients With Overweight and Obesity · NA · completed
NCT04485936 — Evaluation of the Effect of Epitomee Device on Gastric Emptying Rate in Healthy Subjects · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03610958 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Epitomee medical
Last refreshed: 18 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03610958.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing